AMGEN INC 4

Nancy A. Grygiel, SVP & CCO of Amgen Inc., exercised 2,970 stock options and sold 2,970 common shares of AMGN on 2026-08-06 in a largely cashless, tax-covering transaction, ending with 7,340 directly owned shares.

On August 6, 2026, Amgen Inc. SVP & Chief Compliance Officer Nancy A. Grygiel exercised two tranches of non-qualified stock options—1,970 shares at $177.46 and 1,000 shares at $177.31—and immediately sold the same total of 2,970 common shares at $402.1601 per share, primarily to cover the option exercise cost and required withholding taxes, resulting in no net change to her directly held share count from these particular option exercises but leaving her with 7,340 directly owned shares plus additional shares held indirectly through the company’s 401(k) plan. The exercised options, originally granted in 2020 and 2021 with expirations in 2028 and 2029, were in-the-money, and the filing notes that part of her holdings include dividend equivalents tied to unvested RSUs and shares accumulated in the 401(k) stock fund. Based on the transaction prices, the gross sale proceeds were roughly $1.19 million against an exercise cost of about $0.52 million, implying a routine “cashless” exercise structure rather than a discretionary open-market sale, so the economic signal is mainly compensation-related rather than a directional bet on Amgen’s stock.

Filing Facts

CIK

318154

Ticker

AMGN

Form

4

Source Type

fda

Accession

0000318154-26-000129

Alert Tier

8